Pharma BD Deal Intelligence
AstraZeneca's $2.4B all-cash acquisition of Fusion Pharmaceuticals bet on next-generation radiopharmaceuticals, gaining the actinium-225 PSMA-targeted radioconjugate FPI-2265 for metastatic castration-resistant prostate cancer along with Fusion's Ac-225 manufacturing and supply chain. The deal positioned AstraZeneca in radioconjugate therapeutics beyond its existing oncology portfolio, though FPI-2265 remained in development at signing.
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer. AstraZeneca will acquire all of Fusion's shares…
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion, gaining industry-leading radiopharmaceutical R&D, manufacturing, and…
Acquisition of Fusion completed. As a result of the Arrangement, Fusion has become a wholly owned subsidiary of AstraZeneca.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca acquired Fusion Pharmaceuticals for up to approximately $2.4 billion ($21.00 per share upfront plus $3.00 per share contingent value right) in an all-cash arrangement, gaining next-generation actinium-225-based radioconjugate therapeutics and radiopharmaceutical manufacturing capabilities.
FPI-2265 (225Ac-PSMA-I&T) is a Phase 2/3 PSMA-targeted actinium-225 alpha-emitting radioconjugate for metastatic castration-resistant prostate cancer; it competes across three radioligand MOA classes plus established hormonal/chemotherapy backbones. Beta-emitting PSMA radioligands (market-defining incumbent): Pluvicto (lutetium Lu-177 vipivotide tetraxetan, Novartis) is the FDA-approved benchmark (2022 post-taxane; 2025 pre-taxane expansion per PSMAfore) with Novartis reporting roughly $1B 2023 sales scaling toward multi-billion peak; VISION Phase 3 (NEJM 2021) established PSMA-617 as standard. Alpha-emitting PSMA radioligands (direct class competitors): JNJ-6420 / 225Ac-PSMA-617 (J&J/Novartis, Phase 2); BAY 3546828 (Bayer) in Phase 1; TLX591 (177Lu-rosopatamab, Telix) antibody-based PSMA radioconjugate in Phase 3 ProstACT GLOBAL; RAYZ-6434 (Rayze Bio/BMS) pipeline. Alpha-emitting non-PSMA: Xofigo (radium-223 dichloride, Bayer) approved for bone-predominant mCRPC (ALSYMPCA NEJM 2013), Bayer revenue roughly $400M declining as PSMA class expands. Hormonal backbone: Xtandi (enzalutamide, Astellas/Pfizer, ~$7B), Erleada (apalutamide, J&J), Nubeqa (darolutamide, Bayer, ~$1B); Zytiga (abiraterone, J&J/generic); plus taxanes (Taxotere/Jevtana). Commercial threat for FPI-2265: Pluvicto's earlier-line expansion and supply-chain moat, plus J&J's 225Ac-PSMA-617 program via Novartis partnership; actinium-225 supply constraints remain the class-wide rate-limiter.
FPI-1434 is an early-phase actinium-225 radioconjugate targeting IGF-1R, positioning it in an emerging and sparsely populated commercial niche. Direct competition is best read along two axes: the targeted-alpha radiopharmaceutical MOA and non-radioligand IGF-1R blockade. Among alpha-emitter radioligand therapies, Novartis' Pluvicto (lutetium-177 vipivotide tetraxetan, PSMA-targeted, approved 2022, generated roughly $1.4B in 2024) and Bayer's Xofigo (radium-223 dichloride, bone-metastatic CRPC, approved 2013) anchor the market and establish payer pathways for isotopic oncology, though neither shares the IGF-1R target. Within the Ac-225 class specifically, clinical-stage competitors include Bayer/Noria's actinium-PSMA programs and Convergent Therapeutics' CONV-01-alpha (Ac-225 PSMA mAb, Phase 1). On the non-radiopharmaceutical IGF-1R axis, ganitumab (Amgen, IGF-1R mAb) and xentuzumab (Boehringer Ingelheim, IGF-1R/IGF-2 mAb) both failed to demonstrate Phase 3 survival benefit in solid tumors, leaving the target commercially orphaned in non-isotopic formats. Teprotumumab (Tepezza, Amgen/Horizon) is an approved IGF-1R mAb for thyroid eye disease, not oncology, and carries no oncology share. Commercial takeaway: FPI-1434 inherits a tailwind from Pluvicto's radiopharmaceutical commercial playbook but must de-risk IGF-1R targeting where prior antibody efforts flamed out; AstraZeneca is buying a platform bet more than a franchise-threatening asset.
FPI-2059 is a Phase 1 NTSR1-targeted small molecule actinium-225 radioconjugate developed in collaboration with IPSEN/Centre Hospitalier, occupying one of the least-crowded nodes in the targeted radiopharmaceutical landscape. Competitive framing groups along two MOA classes: targeted alpha-emitter radioligands broadly, and NTSR1-directed agents specifically. In the alpha-emitter radioligand class, Bayer's Xofigo (radium-223 dichloride, FDA-approved 2013 for bone-metastatic CRPC) and Novartis' Pluvicto (lutetium-177 vipivotide tetraxetan, approved 2022, ~$1.4B 2024 sales and a beta emitter but the dominant radioligand commercial benchmark) set commercial expectations for isotopic oncology. Novartis' Ac-225-PSMA-617 (Phase 3) and Bayer's targeted thorium conjugate platform further validate the alpha-emitter thesis. Direct NTSR1-targeted competitors are sparse: 3B Pharmaceuticals' 3BP-227 / IPN-1072 (NTSR1-targeted lutetium-177 radioligand, Phase 1, licensed to Ipsen/Novartis) is the closest MOA analog, and academic NTSR1 peptide conjugates (e.g., Erlangen group's Lu-177-3BP-227) remain investigator-initiated. Clovis Oncology's FAP-2286 (FAP-targeted, not NTSR1) competes for the same next-gen radioligand shelf space. Commercial takeaway: FPI-2059 faces minimal direct NTSR1 competition, meaning franchise threat sizing hinges almost entirely on target biology validation and Ac-225 supply constraints rather than share erosion from entrenched competitors.
AstraZeneca completed $2.4B acquisition of Fusion Pharmaceuticals ($21/share + $3 CVR), gaining FPI-2265 actinium-225 PSMA radioconjugate for prostate cancer.
AZ advanced FPI-2265 in mCRPC, building radiopharmaceutical capabilities alongside existing ADC and I/O platforms.
AstraZeneca/Fusion opened a Phase 2 trial (NCT06909825) of the acquired actinium-225 radioconjugate FPI-2265 in combination with olaparib in mCRPC, expanding the radiopharma program beyond monotherapy after deal close.
Fusion gives AZ proprietary actinium-225 platform. FPI-2265 in Phase 2; commercial value depends on clinical success in crowded radiopharma space.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Fusion Pharmaceuticals Inc. (this deal) | 2024 | $2.4B | 64 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2024 deals · AstraZeneca PLC deals · Oncology deals